Congo begins giving experimental Ebola vaccine to medics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Stryker invests $400M in CMR Surgical with option to acquire
- Cerebras Systems hits new 52-week low on unlock concerns
- Enovix posts $11M in Q3 revenue, beats guidance by 10%
Goldman Sachs Says Merck (MRK) 'Likely to be the Dominant Player in All of NSCLC'
May 23, 2018 9:26 AM EDTMerck (NYSE: MRK) announced that its phase 3 trial in 1L squamous NSCLC, KN-407 met its dual primary endpoint of OS and PFS based on an interim analysis conducted by the DMC. Goldman Sachs expects full data at ASCO and anticipated this update after... More
Merck (MRK) Declares $0.48 Quarterly Dividend; 3.3% Yield
May 22, 2018 2:51 PM EDTMerck (NYSE: MRK) declared a quarterly dividend of $0.48 per share, or $1.92 annualized.
The dividend will be payable on July 9, 2018, to stockholders of record on June 15, 2018, with an ex-dividend date of June 14, 2018.
The annual yield on the dividend is 3.3 percent.
For a... More



